• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
HealthMark Cuban

Mark Cuban opens his own online pharmacy

By
Chris Morris
Chris Morris
Former Contributing Writer
Down Arrow Button Icon
By
Chris Morris
Chris Morris
Former Contributing Writer
Down Arrow Button Icon
January 20, 2022, 11:05 AM ET

Mark Cuban has added another title to his multi-hyphenate résumé: drugstore owner.

The entrepreneur–Dallas Mavericks owner–Shark Tank host–crypto enthusiast has launched the Mark Cuban Cost Plus Drug Company, an online pharmacy that promises lower prices on over 100 medications, including ones commonly prescribed for high cholesterol and hypertension.

To lower costs, Cuban cut out the middleman, setting up his own pharmaceutical wholesaler and negotiating directly with drug manufacturers and pharmacies for rebates and discounts. It sells the drugs at a 15% markup and an added $3 pharmacist fee. Shipping is $5.

Among the discounted drugs is mesalamine, which treats ulcerative colitis. Normally, that retails for $940 per month, which falls as low as $102 per month with vouchers. Cuban Cost Plus will sell it for $32.40 per month. Atorvastatin (a generic version of cholesterol medicine Lipitor) generally sells for $55.08, but will cost $3.60 on Cuban Cost Plus, the company website said.

“There are numerous bad actors in the pharmaceutical supply chain preventing patients from getting affordable medicines,” said CEO Alex Oshmyansky in a statement. “The markup on potentially lifesaving drugs that people depend on is a problem that can’t be ignored. It is imperative that we take action and help expand access to these medications for those who need them most.”

The venture will not accept insurance payments at this time, requiring cash, but it claims its prices are still below what patients would pay with insurance at a typical pharmacy.

The online pharmacy, which stealth-launched under a different name in 2018, was sparked after so-called pharma bro Martin Shkreli dramatically raised the price of certain essential drugs and became a lightning rod for consumer ire over drug prices.

Never miss a story: Follow your favorite topics and authors to get a personalized email with the journalism that matters most to you.

About the Author
By Chris MorrisFormer Contributing Writer

Chris Morris is a former contributing writer at Fortune, covering everything from general business news to the video game and theme park industries.

See full bioRight Arrow Button Icon

Latest in Health

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

Latest in Health

PoliticsModerna
FDA backtracks and agrees to review Moderna mRNA flu vaccine after initial rejection
By Lauran Neergaard and The Associated PressFebruary 18, 2026
3 hours ago
Healthsleep
The 4 Best Bed Frames of 2026: Expert Tested
By Christina SnyderFebruary 18, 2026
6 hours ago
Successthe future of work
As boomer and Gen X bosses retire, working from home will make a major comeback, new research predicts—and you have work-life balance loving Gen Z to thank
By Orianna Rosa RoyleFebruary 17, 2026
1 day ago
HealthHealth
Confronting Asia’s growing rate of chronic conditions means tackling cultural issues as much as medical ones
By Stuart A. SpencerFebruary 15, 2026
3 days ago
Susan Blumenthal
AICancer
Meet the American spies who helped mammograms save more lives
By Erik GermanFebruary 15, 2026
3 days ago
HealthDietary Supplements
5 Best Nootropics of 2026: Expert Reviewed Supplements
By Christina SnyderFebruary 13, 2026
5 days ago

Most Popular

placeholder alt text
AI
Thousands of CEOs just admitted AI had no impact on employment or productivity—and it has economists resurrecting a paradox from 40 years ago
By Sasha RogelbergFebruary 17, 2026
1 day ago
placeholder alt text
Personal Finance
You need $2 million to retire and 'almost no one is close,' BlackRock CEO warns, a problem that Gen X will make 'harder and nastier'
By Sydney LakeFebruary 17, 2026
1 day ago
placeholder alt text
Economy
Trump crackdown drives 80% plunge in immigrant employment, reshaping labor market, Goldman says
By Nick LichtenbergFebruary 17, 2026
1 day ago
placeholder alt text
Economy
$56 trillion national debt leading to a spiraling crisis: Budget watchdog warns the U.S. is walking a crumbling path
By Nick LichtenbergFebruary 17, 2026
1 day ago
placeholder alt text
Personal Finance
Current price of silver as of Tuesday, February 17, 2026
By Joseph HostetlerFebruary 17, 2026
1 day ago
placeholder alt text
Commentary
Something big is happening in AI — and most people will be blindsided
By Matt ShumerFebruary 11, 2026
7 days ago

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.